Nature Reviews Cardiology, Published online: 28 January 2025; doi:10.1038/s41569-025-01129-yA new study shows how obesity can disrupt a cholesterol metabolism in a particular subset of metabolically protective regulatory T cells in visceral adipose tissue.

Nature Reviews Cardiology, Published online: 28 January 2025; doi:10.1038/s41569-025-01126-1In this Review, Fabiani and colleagues summarize the management of anthracycline cardiotoxicity, including mechanisms, classification, risk stratification, prevention, diagnosis and treatment. The authors also discuss permissive treatment strategies and the use of cardioprotective drugs.

Nature Reviews Cardiology, Published online: 21 January 2025; doi:10.1038/s41569-025-01123-4In this Tools of the Trade article, Lyall discusses the use of traction force microscopy to assess the contractile function of individual cardiomyocytes.

Nature Reviews Cardiology, Published online: 20 January 2025; doi:10.1038/s41569-025-01118-1The past 20 years have witnessed remarkable progress in the evolution of transcatheter procedures for the treatment of adult patients with congenital heart disease. In this Review, Rodés-Cabau and colleagues provide a comprehensive overview of the available transcatheter interventions for these patients, focusing on their current indications and associated outcomes.

Nature Reviews Clinical Oncology, Published online: 27 January 2025; doi:10.1038/s41571-025-00990-7Early promising results with addition of an ICI and an anti-angiogenic to TACE

Nature Reviews Clinical Oncology, Published online: 24 January 2025; doi:10.1038/s41571-025-00987-2Recent results from the phase III AQUILA trial demonstrate the benefit of fixed-duration monotherapy with daratumumab over observation in patients with high-risk smouldering multiple myeloma, which changes the early interception treatment landscape. Herein, we discuss how future studies could build on this success and pave the way to eradicating multiple myeloma before it starts.

Nature Reviews Clinical Oncology, Published online: 20 January 2025; doi:10.1038/s41571-024-00985-wAnalysis of circulating tumour DNA (ctDNA) is commonly used for molecular profiling in patients with advanced-stage non-small-cell lung cancer (NSCLC). The authors of this Review summarize the available evidence on the potential utility of incorporating ctDNA in the management of those with early stage and locally advanced NSCLC and propose interventional studies to provide the necessary additional evidence.

Nature Reviews Clinical Oncology, Published online: 06 January 2025; doi:10.1038/s41571-024-00979-8Despite lower levels of most targetable alterations, a strong association with a history of smoking and generally higher levels of PD-L1 expression, patients with squamous non-small-cell lung cancer (LUSC) have inferior outcomes on immune-checkpoint inhibitors (ICIs) compared to those with non-squamous disease. In this Review, the authors describe the available evidence on the role of ICIs and of potential novel therapies in patients with LUSC, as well as highlighting important unresolved challenges and future research directions in this historically overlooked subtype.